Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular study

Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy

Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL

Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia

Barentz acquires Anshul Life Sciences to strengthen India portfolio

The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024

USAID and Takeda launch dengue prevention campaign

Campaign launched to spread awareness regarding dengue prevention and control

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands

Alembic receives USFDA’s final approval for Fluphenazine Hydrochloride Tablets

Bayer announces positive topline results for Nubeqa from Phase III trial in men with mHSPC

Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT

Singhi Advisors facilitates acquisition of 85% stake of GMP Technical Solutions by Japanese Shinryo Corporation

This transaction is the third acquisition by three different Japanese players in this segment

Elucid appoints Kelly Huang as CEO

Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software